Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amphotericin B colloidal dispersion.

R Patel1

  • 1Division of Infectious Diseases and Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. patel.robin@mayo.edu

Expert Opinion on Pharmacotherapy
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Involvement of PKC-iota in glioma proliferation.

Cell proliferation·2008
Same author

Evaluating the role of HLA-DQ polymorphisms on immune response to bacterial superantigens using transgenic mice.

Tissue antigens·2007
Same author

Varicella zoster virus-associated disease in adult kidney transplant recipients: incidence and risk-factor analysis.

Transplant infectious disease : an official journal of the Transplantation Society·2007
Same author

Vancomycin-resistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients.

Bone marrow transplantation·2007
Same author

Nasal and nasopharyngeal lymphoma in cats: 50 cases (1989-2005).

Veterinary pathology·2007
Same author

Current management strategies for the treatment and prevention of cytomegalovirus infection in solid organ transplant recipients.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

CURRENT ADVANCES IN PHARMACOTHERAPEUTIC STRATEGIES FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS.

Expert opinion on pharmacotherapy·2026
Same journal

Emerging synthetic drugs for the management of hidradenitis suppurativa: a comprehensive update.

Expert opinion on pharmacotherapy·2026
See all related articles

Amphotericin B colloidal dispersion (ABCD) offers an effective alternative to conventional amphotericin B deoxycholate for treating invasive fungal infections, with reduced nephrotoxicity but more infusion-related adverse events.

Area of Science:

  • Mycology
  • Pharmacology
  • Infectious Diseases

Background:

  • Amphotericin B colloidal dispersion (ABCD) is a lipid-based formulation of amphotericin B.
  • It exhibits reduced nephrotoxicity compared to amphotericin B deoxycholate.
  • Infusion-related adverse events are more common with ABCD than with liposomal amphotericin B.

Purpose of the Study:

  • To evaluate the efficacy and safety of ABCD as an alternative antifungal therapy.
  • To compare ABCD with other lipid formulations of amphotericin B.
  • To discuss the role of ABCD in treating invasive fungal infections in immunocompromised patients.

Main Methods:

  • Review of randomized, double-blind studies.
  • Analysis of non-comparative, open-label clinical trials.

Related Experiment Videos

  • Comparison with existing amphotericin B formulations.

    • Main Results:

    • ABCD is effective for empirical treatment of fever and neutropenia.
    • It shows activity against invasive Candida and Aspergillus infections.
    • Approved for invasive aspergillosis when amphotericin B deoxycholate is not suitable.

    Conclusions:

    • ABCD is a viable alternative to amphotericin B deoxycholate, especially in patients with renal impairment or intolerance.
    • Higher incidence of infusion-related events necessitates careful monitoring.
    • High cost is a consideration for all lipid formulations of amphotericin B.